OVA DNA origami vaccine

The OVA DNA origami vaccine is a preclinical nanotherapeutic platform that utilizes the structural precision of DNA origami to co-deliver antigens and adjuvants. In this system, the model antigen ovalbumin (OVA), typically in the form of peptides like SIINFEKL, and synthetic DNA adjuvants such as CpG oligonucleotides are precisely positioned on a DNA nanostructure scaffold (e.g., a rectangular sheet or tubular structure). This spatial organization is designed to mimic the geometric presentation of pathogens, thereby enhancing uptake by dendritic cells and the subsequent activation of Toll-like receptor 9 (TLR9). The platform has been primarily developed and studied by researchers at the National Center for Nanoscience and Technology (NCNST) in China to demonstrate the potential of DNA nanotechnology in inducing robust CD8+ T-cell mediated anti-tumor immunity, particularly in B16-OVA melanoma mouse models.

Other names

DNA origami-OVA-CpG vaccineOvalbumin DNA origami vaccineDNA origami-based OVA vaccine